Globally, the size of the Biopharmaceutical contract manufacturing market size was about USD 6 billion in 2019. It is expected to rise at a CAGR of 9.10% to grow to a value of USD 9.27 billion by 2024.
Biopharmaceuticals is a biological product manufactured and developed to address the prevention and treatment of various diseases. Recent advancements in biomanufacturing and biotechnology have triggered the growth of innovative technologies that are capable of addressing the difficulties related to the manufacture of Biopharmaceuticals. Consequently, there is a rise in the Global Biopharmaceutical contract manufacturing market growth.
Previously, the Biopharmaceutical market was aimed at preventive Biopharmaceuticals and mass production against infectious diseases. The commencement of therapeutic Biopharmaceuticals has altered interest in the field by creating a method for Biopharmaceuticals to be industrialized for a variety of chronic and progressive ailments, which has endorsed the entry of a number of manufacturers and budding investors who are contending for a market investment in this potential market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Product Type, Therapeutic Area, Application and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Patheon N.V., Rentschler Biotechnologie GmbH, AbbVie Contract Manufacturing (An AbbVie Company), Biomeva GmbH, Boehringer Ingelheim GmbH, WuXi Biologics, Abzena Plc, Lonza Group AG, Probiogen AG, Sandoz International GmbH, Fujifilm Diosynth Biotechnologies, KBI Biopharma, Inc., Cytovance Biologics, Inc., Baxter Biopharma Solutions, Vetter Pharma International GmbH, Catalent, Inc., Samsung Biologics Co., Ltd., and Ajinomoto Althea, Inc. |
This research report on the Global Biopharmaceutical Contract Manufacturing Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Biopharmaceutical Contract Manufacturing Market Analysis – By Product Type:
Biopharmaceutical Contract Manufacturing Market Analysis – By Therapeutic Area:
Biopharmaceutical Contract Manufacturing Market Analysis – By Application:
Regional Analysis:
North America takeovers the global market largely based on the concept of market collaborations and agreements, as key business strategies lead to growth and expansion across the globe. Such large organizations are also buying minor scale biopharmaceutical companies in the Asia Pacific region to reinforce their market presence. The Oncology area is witnessing a large growth owing to an increase in cancer-related diseases. The market has also observed growth in Research and Development and a surge in innovative developments in manufacturing.
Key players dominating the Global Biopharmaceutical Contract Manufacturing Market profiled in this report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Growth Factors
5.1.5 Interferons
5.1.6 Recombinant Protiens
5.1.7 Vaccines
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Product Type
5.1.10 Market Attractiveness Analysis, By Product Type
5.1.11 Market Share Analysis, By Product Type
5.2 Therapeutic Area
5.2.1 Introduction
5.2.2 Infectious Disease
5.2.3Cardiovascular Disease
5.2.4 Oncology
5.2.5 Metabolic Disease
5.2.6 Respiratory Disorder
5.2.7 Autoimmune Disease
5.2.8 Neurology
5.2.9 Ophthalmology
5.2.10 Others
5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area
5.2.12 Market Attractiveness Analysis, By Therapeutic Area
5.2.13 Market Share Analysis, By Therapeutic Area
5.3 Application
5.3.1 Introduction
5.3.2 Clinical
5.3.3 Commercial
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Therapeutic Area
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Therapeutic Area
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Therapeutic Area
6.1.5.4 By Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Patheon N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2Rentschler Biotechnologie GmbH
8.3 AbbVie Contract Manufacturing (An AbbVie Company)
8.4 Biomeva GmbH
8.5 Boehringer Ingelheim GmbH
8.6 WuXi Biologics
8.7 Abzena Plc
8.8 Lonza Group AG
8.9 Samsung Biologics Co.
8.10 Ajinomoto Althea, Inc.
8.11 Fujifilm Diosynth Biotechnologies
8.12 Probiogen AG
8.13 Sandoz International GmbH
8.14 KBI Biopharma, Inc.
8.15 Baxter Biopharma Solutions
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
